GLP-1/GIP Dual Agonist
The Tirzepatide File
FDA Approved (Mounjaro, Zepbound) · Eli Lilly
Strong Evidence
Eli Lilly's dual agonist. FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). The current market leader before retatrutide arrives.
Mechanism
Dual agonist targeting both GLP-1 and GIP receptors for enhanced metabolic effects
Key Data
weight Loss
~22.5% at highest dose (SURMOUNT-1)
approval Status
FDA approved 2023 (Zepbound for weight loss)
brand Names
- · Mounjaro
- · Zepbound
common Side Effects
- · Nausea
- · Diarrhea
- · Reduced appetite
Full Article Coming Soon
The full The Tirzepatide File will cover mechanism of action, clinical trial evidence, dosage data, side effects, comparisons, and FAQs — all evidence-rated and referenced. Check back soon.
This content is for informational purposes only. Not medical advice. Always consult a qualified healthcare provider before making any health decisions.